News CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
55.05 ^USD	-1.98%		-9.26%	-12.06%

Apr. 18	Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	MT
Apr. 17	Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	Apr. 18	MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	Apr. 17	MT
Harvard University: How to realize immense promise of gene editing	Apr. 17	AQ
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference	Apr. 03	AQ
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	Apr. 01	AQ
Recent Appellate Decision Overturns Revocations Of Broad Institute CRISPR-Cas9 Patents	Mar. 26	AQ
CRISPR Therapeutics Proposes New Appointment to the Board of Directors	Mar. 13	AQ
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating	Mar. 06	MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating	Feb. 26	MT
Wells Fargo Raises Price Target on CRISPR Therapeutics to $70 From $55, Maintains Equal-Weight Rating	Feb. 22	MT
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating	Feb. 22	MT
Chardan Ups Price Target on CRISPR Therapeutics to $112 From $110, Keeps Buy Rating	Feb. 22	MT
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept	Feb. 22	MT
Transcript : CRISPR Therapeutics AG Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 10:00 AM	Feb. 21
Needham Adjusts CRISPR Therapeutics' Price Target to $90 From $88, Keeps Buy Rating	Feb. 21	MT
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	Feb. 21	MT
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M	Feb. 21	MT
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10	Feb. 21	MT
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Summary

Filters